Show simple item record

dc.contributor.authorMackey, J.
dc.contributor.authorPienkowski, T.
dc.contributor.authorCrown, J.
dc.contributor.authorSadeghi, S.
dc.contributor.authorMartin, M.
dc.contributor.authorChan, Arlene
dc.contributor.authorSaleh, M.
dc.contributor.authorSehdev, S.
dc.contributor.authorProvencher, L.
dc.contributor.authorSemiglazov, V.
dc.contributor.authorPress, M.
dc.contributor.authorSauter, G.
dc.contributor.authorLindsay, M.
dc.contributor.authorHoué, V.
dc.contributor.authorBuyse, M.
dc.contributor.authorDrevot, P.
dc.contributor.authorHitier, S.
dc.contributor.authorBensfia, S.
dc.contributor.authorEiermann, W.
dc.contributor.authorTranslational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in
dc.date.accessioned2017-11-24T05:26:08Z
dc.date.available2017-11-24T05:26:08Z
dc.date.created2017-11-24T04:48:55Z
dc.date.issued2016
dc.identifier.citationMackey, J. and Pienkowski, T. and Crown, J. and Sadeghi, S. and Martin, M. and Chan, A. and Saleh, M. et al. 2016. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.. Annals of Oncology. 27 (6): pp. 1041-1047.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/58543
dc.identifier.doi10.1093/annonc/mdw098
dc.description.abstract

BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety. PATIENTS AND METHODS: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC ? T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography. RESULTS: The 10-year DFS rates were 66.5% in the AC ? T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC ? T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC ? T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy. CONCLUSION: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC ? T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00312208.

dc.publisherOxford University Press
dc.titleLong-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
dc.typeJournal Article
dcterms.source.volume27
dcterms.source.number6
dcterms.source.startPage1041
dcterms.source.endPage1047
dcterms.source.issn1569-8041
dcterms.source.titleAnnals of Oncology
curtin.departmentCurtin Medical School
curtin.accessStatusOpen access via publisher


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record